The first 60 days: Oesophageal squamous cell carcinoma
Squamous cell carcinoma of the oesophagus, the world's commonest form, is linked to smoking, alcohol and very hot drinks and sits in the upper and middle gullet. It is treated with chemoradiation, with or without surgery, and immunotherapy has recently joined chemotherapy for advanced disease. Below, week by week, is what OnCo's record of Oesophageal squamous cell carcinoma says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- SurgeonNamed in the standard of care for: Early (T1a), Locally advanced.
- Medical oncologistNamed in the standard of care for: Early (T1a), Locally advanced, Metastatic, first line.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Early (T1a), Locally advanced.
- Palliative and supportive care teamNamed in the standard of care for: Prevention and screening.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Smoking cessation, alcohol reduction, avoiding very hot drinks; endoscopic screening in high-incidence regions of China.
Endoscopic submucosal dissection; oesophagectomy or chemoradiation if deeper invasion is found.
Neoadjuvant carboplatin-paclitaxel chemoradiation and surgery (CROSS), or definitive cisplatin-fluorouracil chemoradiation with surgery reserved for persistent disease; adjuvant nivolumab after incomplete response (CheckMate 577).
Nivolumab plus chemotherapy or nivolumab plus ipilimumab (CheckMate 648), or pembrolizumab plus chemotherapy (KEYNOTE-590).
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example PD-L1 combined positive score or tumour proportion score, TP53 and NOTCH1 mutations, Endoscopic Lugol staining for early lesions, Pathological response after chemoradiation), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Upper and middle third squamous cell carcinoma, Earlysquamous cell carcinoma, Locally advanced.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Early (T1a)
- For my situation (early (t1a)), which of the standard options do you recommend and why?Guideline options include: Endoscopic submucosal dissection; oesophagectomy or chemoradiation if deeper invasion is found.
Locally advanced
- For my situation (locally advanced), which of the standard options do you recommend and why?Guideline options include: Neoadjuvant carboplatin-paclitaxel chemoradiation and surgery (CROSS), or definitive cisplatin-fluorouracil chemoradiation with surgery reserved for persistent disease; adjuvant nivolumab after incomplete response (CheckMate 577).
- Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, Cisplatin or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of CROSS and CheckMate 577 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Metastatic, first line
- For my situation (metastatic, first line), which of the standard options do you recommend and why?Guideline options include: Nivolumab plus chemotherapy or nivolumab plus ipilimumab (CheckMate 648), or pembrolizumab plus chemotherapy (KEYNOTE-590).
- Am I a candidate for Nivolumab, Ipilimumab, Pembrolizumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of CheckMate 648 and KEYNOTE-590 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Prevention and screening
- For my situation (prevention and screening), which of the standard options do you recommend and why?Guideline options include: Smoking cessation, alcohol reduction, avoiding very hot drinks; endoscopic screening in high-incidence regions of China.
Any stage
- Are there clinical trials I could join, for example of Nivolumab, Tislelizumab?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Whether surgery can be omitted after a complete response to chemoradiation”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Most cases worldwide present late without access to endoscopy”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Oesophageal squamous cell carcinoma: the full pageSquamous cell carcinoma of the oesophagus, the world's commonest form, is linked to smoking, alcohol and very hot drinks and sits in the upper and middle gullet. It is treated with chemoradiation, with or without surgery, and immunotherapy has recently joined chemotherapy for advanced disease.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.